http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho, Byoung Chul,Im, Chong-Kun,Park, Moo-Suk,Kim, Se Kyu,Chang, Joon,Park, Jong Pil,Choi, Hye Jin,Kim, Yu Jin,Shin, Sang-Joon,Sohn, Joo Hyuk,Kim, Hoguen,Kim, Joo Hang Grune Stratton ; American Society of Clinical Onco 2007 Journal of clinical oncology Vol.25 No.18
<P>This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib.</P>
Rhee, Young Sun,Yun, Young Ho,Park, Sohee,Shin, Dong Ok,Lee, Kwang Mi,Yoo, Han Jin,Kim, Jeong Hwa,Kim, Soon Ok,Lee, Ran,Lee, Youn Ok,Kim, Nam Shin Grune Stratton ; American Society of Clinical Onco 2008 Journal of clinical oncology Vol.26 No.36
<P>PURPOSE: The purpose of this study was to explore the prevalence of and to identify the predictors of depression in family caregivers of cancer patients. PATIENTS AND METHODS: We enrolled 310 caregivers of cancer patients from the National Cancer Center, Korea, on this study and obtained demographic information for both patients and caregivers. To assess caregiver depression and its predictors, we used the Beck Depression Inventory (BDI), the Caregiver Quality of Life Index-Cancer, and the Family Impact Questionnaire. We used logistic regression analysis to identify independent predictors of caregiver depression. RESULTS: The majority (67%) of caregivers had high depression scores (BDI > 13), and 35% had very high depression scores (BDI > 21). In a multiple logistic regression model, caregivers who were women, the spouse of the patient, in poor health, feeling burdened, adapting poorly, unable to function normally, or caring for a patient with poor Eastern Cooperative Oncology Group performance status were more likely to experience depression (P < .01 for all values). CONCLUSION: Depression was highly prevalent among cancer patient family caregivers, and care burden was its best predictor. Interventions aimed at reducing the psychiatric effects of cancer should focus not only on the patient but also on the caregiver.</P>
Hughes, Timothy,Saglio, Giuseppe,Branford, Susan,Soverini, Simona,Kim, Dong-Wook,Mü,ller, Martin C,Martinelli, Giovanni,Cortes, Jorge,Beppu, Lan,Gottardi, Enrico,Kim, Dongho,Erben, Philipp,Shou, Y Grune Stratton ; American Society of Clinical Onco 2009 Journal of clinical oncology Vol.27 No.25
<P>PURPOSE: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed. PATIENTS AND METHODS: Baseline mutation data were assessed in 281 (88%) of 321 patients with CML-CP in the phase II nilotinib registration trial. RESULTS: Among imatinib-resistant patients, the frequency of mutations at baseline was 55%. After 12 months of therapy, major cytogenetic response (MCyR) was achieved in 60%, complete cytogenetic response (CCyR) in 40%, and major molecular response (MMR) in 29% of patients without baseline mutations versus 49% (P = .145), 32% (P = .285), and 22% (P = .366), respectively, of patients with mutations. Responses in patients who harbored mutations with high in vitro sensitivity to nilotinib (50% inhibitory concentration [IC(50)] <or= 150 nM) or mutations with unknown nilotinib sensitivity were equivalent to those responses for patients without mutations (not significant). Patients with mutations that were less sensitive to nilotinib in vitro (IC(50) > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, respectively, achieved MCyR; none achieved CCyR. CONCLUSION: For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response. However, mutational status at baseline may influence response. Less sensitive mutations that occurred at three residues defined in this study, as well as the T315I mutation, may be associated with less favorable responses to nilotinib.</P>
Obesity and risk of cancer in postmenopausal Korean women.
Song, Yun-Mi,Sung, Joohon,Ha, Mina Grune Stratton ; American Society of Clinical Onco 2008 Journal of clinical oncology Vol.26 No.20
<P>PURPOSE: To evaluate an association between obesity, measured by body mass index (BMI; kg/m(2)), and risk of cancer at individual and all sites in postmenopausal women. METHODS: A cohort of 170,481 postmenopausal Korean women who were age 40 to 64 years at baseline measurement of BMI was observed prospectively from 1994 to 2003 for cancer incidence. Multivariable adjusted proportional hazard models were used for evaluating the association. RESULTS: Women with a BMI of 30 kg/m(2) or higher had a 23% higher risk of cancer than women with a BMI between 21.0 and 22.9 kg/m(2) (hazard ratio = 1.23; 95% CI, 1.08 to 1.41). According to the increase in BMI level, significant positive trends existed in cancers of colon, breast, corpus uteri, and kidney with hazard ratios of 1.05 (95% CI, 1.02 to 1.08), 1.07 (95% CI, 1.05 to 1.10), 1.13 (95% CI, 1.07 to 1.20), and 1.08 (95% CI, 1.02 to 1.15), respectively, for the increase of BMI by 1 kg/m(2). When the analysis was limited to never-smokers, women with a BMI of 25 kg/m(2) or higher showed a significantly increased risk of cancers of the colon, breast, corpus uteri, and kidney and leukemia compared with the normal BMI (18.5 to 22.9 kg/m(2)) group. CONCLUSION: Although variations exist between the individual cancer sites, obesity was associated with an overall increased risk of cancer in postmenopausal Korean women. To reduce the risk of cancer, active strategies to prevent obesity should be implemented in postmenopausal women.</P>
Reduction and cessation of cigarette smoking and risk of cancer: a cohort study of Korean men.
Song, Yun-Mi,Sung, Joohon,Cho, Hong-Jun Grune Stratton ; American Society of Clinical Onco 2008 Journal of clinical oncology Vol.26 No.31
<P>PURPOSE: Reducing cigarette smoking has been proposed as a method of harm reduction. The effect of smoking reduction on cancer risk has not been studied in Asian populations. PATIENTS AND METHODS: A total of 479,156 Korean men, age 30 to 58 years, were stratified into nine groups based on smoking status in 1990 and 1992. From 1992 to 2003, patients were observed and tested for the occurrence of cancer. RESULTS: There was no association between smoking reduction and risk of all cancers. However, the risk of smoking-related cancers tended to decrease, though not significantly, when heavy smokers (> or = 20 cigarettes/d) became moderate smokers (10 to 19 cigarettes/d), with a hazard ratio (HR) of 0.91 (95% CI, 0.82 to 1.02). For lung cancer, patients who reduced from heavy to moderate smoking and from heavy to light smoking (< 10 cigarettes/d) had significantly decreased risks based on multivariable-adjusted HRs (HR = 0.72, 95% CI, 0.49 to 0.89; HR = 0.63, 95% CI, 0.46 to 0.84, respectively). Study participants who never smoked, sustained ex-smokers, and quitters had lower risks for all cancers, smoking-related cancers, and lung cancer in a dose-response manner as compared with heavy smokers. CONCLUSION: Smoking reduction was associated with a significant decrease in the risk of lung cancer, but the size of risk reduction was disproportionately smaller than that expected from the reduced amount of cigarette consumption. Although smoking cessation should be the cornerstone of preventing smoking-related cancers, smoking reduction could be considered as a strategy to supplement smoking cessation for those who are unable to quit smoking immediately.</P>
Shin, Dong Wook,Kim, So Young,Cho, Juhee,Sanson-Fisher, Robert W,Guallar, Eliseo,Chai, Gyu Young,Kim, Hak-Soon,Park, Bo Ram,Park, Eun-Cheol,Park, Jong-Hyock Grune Stratton ; American Society of Clinical Onco 2011 Journal of clinical oncology Vol.29 No.33
<P>Identification of supportive care needs in patients with cancer is essential for planning appropriate interventions. We aimed to determine patient-physician concordance in perceived supportive care needs in cancer care and to explore the predictors and potential consequences of patient-physician concordance.</P>
Yun, Young Ho,Lee, Myung Kyung,Park, Sohee,Lee, Jung Lim,Park, Jeanno,Choi, Youn Seon,Lim, Yeun Keun,Kim, Sam Yong,Jeong, Hyun Sik,Kang, Jung Hun,Oh, Ho-Suk,Park, Ji Chan,Kim, Si-Young,Song, Hong Suk Grune Stratton ; American Society of Clinical Onco 2011 Journal of clinical oncology Vol.29 No.36
<P>We tested whether a decision aid explaining how to discuss the approach of death with a family member with cancer would help family caregivers decide to discuss a terminal prognosis.</P>
Association of family history with cancer recurrence and survival in patients with gastric cancer.
Han, Mi Ah,Oh, Myueng Guen,Choi, Il Ju,Park, Sook Ryun,Ryu, Keun Won,Nam, Byung-Ho,Cho, Soo-Jeong,Kim, Chan Gyoo,Lee, Jun Ho,Kim, Young-Woo Grune Stratton ; American Society of Clinical Onco 2012 Journal of clinical oncology Vol.30 No.7
<P>Family history of gastric cancer is a major risk factor for the disease. In this study, we investigated the prognoses of patients with gastric cancer with a family history.</P>